Both products deliver dry powder asthma medication through Teva’s RespiClick inhaler.
The AirDuo RespiClick contains the same active ingredients as GlaxoSmithKline’s inhaler drug Advair, while the ArmonAir RespiClick contains the same active ingredients as GSK’s other asthma drug Flovent. Both inhalers are intended to treat asthma in adults 12 years and older.
Teva expects both products to be available in the U.S. later this year.
More articles on supply chain:
Target launches new guidelines to control chemicals in its supply chain
Shark antibodies could successfully transport drugs to brain
Mylan CEO speaks out for 1st time since congressional hearing: 5 quotes
